Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery
- PMID: 22673172
- DOI: 10.1016/S1701-2163(16)35272-0
Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery
Abstract
Objective: The objective of this study was to examine both overall and disease-free survival of patients with advanced stage ovarian cancer after immediate or interval debulking surgery based on residual disease.
Methods: We performed a retrospective chart review at the Tom Baker Cancer Centre in Calgary, Alberta of patients with pathologically confirmed stage III or IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between 2003 and 2007. We collected data on the dates of diagnosis, recurrence, and death; cancer stage and grade, patients' age, surgery performed, and residual disease.
Results: One hundred ninety-two patients were included in the final analysis. The optimal debulking rate with immediate surgery was 64.8%, and with interval surgery it was 85.9%. There were improved overall and disease-free survival rates for optimally debulked disease (< 1 cm) with both immediate and interval surgery (P < 0.001) compared to suboptimally debulked disease. Overall survival rates for optimally debulked disease were not significantly different in patients having immediate and interval surgery (P = 0.25). In the immediate surgery group, patients with microscopic residual disease had better disease-free survival (P = 0.015) and overall survival (P = 0.005) than patients with < 1 cm residual disease. In patients who had interval surgery, those who had microscopic residual disease had more improved disease-free survival than those with < 1 cm disease (P = 0.05), but they did not have more improved overall survival (P = 0.42). Patients with microscopic residual disease who had immediate surgery had a significantly better overall survival rate than those who had interval surgery (P = 0.034).
Conclusion: In women with advanced stage ovarian cancer, the goal of surgery should be resection of disease to microscopic residual at the initial procedure. This results in improved overall survival than lesser degrees of resection. Further studies are required to determine optimal surgical management.
Similar articles
-
A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.Am J Obstet Gynecol. 2019 Oct;221(4):326.e1-326.e7. doi: 10.1016/j.ajog.2019.05.006. Epub 2019 May 10. Am J Obstet Gynecol. 2019. PMID: 31082382
-
Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?Gynecol Oncol. 2018 Aug;150(2):233-238. doi: 10.1016/j.ygyno.2018.06.015. Epub 2018 Jun 20. Gynecol Oncol. 2018. PMID: 29933927
-
Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer.Int J Gynecol Cancer. 2020 Jul;30(7):1052-1057. doi: 10.1136/ijgc-2020-001466. Epub 2020 Jun 2. Int J Gynecol Cancer. 2020. PMID: 32487686
-
Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.Cochrane Database Syst Rev. 2018 Oct 8;10(10):CD012567. doi: 10.1002/14651858.CD012567.pub2. Cochrane Database Syst Rev. 2018. PMID: 30298516 Free PMC article.
-
Cytoreductive surgery for advanced ovarian cancer.Womens Health (Lond). 2014 Mar;10(2):179-90. doi: 10.2217/whe.14.4. Womens Health (Lond). 2014. PMID: 24601809 Review.
Cited by
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?Biomedicines. 2022 Aug 29;10(9):2113. doi: 10.3390/biomedicines10092113. Biomedicines. 2022. PMID: 36140214 Free PMC article. Review.
-
Secondary surgical cytoreduction needs to be assessed taking into account surgical technique, completeness of cytoreduction, and extent of disease.World J Surg Oncol. 2020 May 11;18(1):92. doi: 10.1186/s12957-020-01853-4. World J Surg Oncol. 2020. PMID: 32393274 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical